Metoject subcutaneous injection 12.5mg syringe 0.25mL

Metoject subcutaneous injection 12.5mg syringe 0.25mL, manufactured by Japan Medac, contains methotrexate. Methotrexate is an antimetabolite and immunosuppressant indicated for various cancers, autoimmune diseases such as rheumatoid arthritis, juvenile idiopathic arthritis, and severe psoriasis. It acts by inhibiting nucleotide synthesis and modulating immune function. It is supplied as a 12.5mg/0.25mL/1 tube injectable drug (YJ code: 3999468G3020).